Please assess the completion status of the following clinical trial:

Trial Title: Progesterone Effect on Individuals Diagnoses With AD and PTSD.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ages 21 to 60;~2. Current diagnosis of AD and PTSD;~3. Drink regularly are not in an active phase of alcohol withdrawal;~4. Not at risk for suicide;~5. Not taking regularly psychoactive drugs including anxiolytics and antidepressants;~6. For women, have regular menses every 25-35 days.~Exclusion Criteria:~1. Current SCID diagnosis of any psychotic disorder;~2. Substance dependence (other than alcohol and nicotine) in the past 30 days;~3. Current unstable medical condition;~4. Positive test results at more than one baseline appointment on urine drug screens conducted for opiates, cocaine, marijuana, benzodiazepines, and barbiturates; for women, amenorrhea, use of oral contraceptives;~5. Known allergy to progesterone or peanuts (vehicle for micronized progesterone);~6. History of thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or Bleeding disorders, heart disease, diabetes or history of stroke.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Progesterone (Type: EXPERIMENTAL): For the three days prior to each test day every participant in this arm will receive one progesterone capsule (200 mg. bid) on the first day and 2 progesterone capsules per day for days 2 and 3. On the test day the participant will receive the last progesterone capsule (200 mg.bid). On the test day two scripts will be read one trauma related script (most traumatic experience) and one neutral script (relaxed scene given by participant)
- Placebo (Type: PLACEBO_COMPARATOR): For the three days prior to each test day every participant in this arm will receive one placebo capsule on the first day and 2 placebo capsules per day for days 2 and 3. On the test day the participant will receive the last placebo capsule. On the test day two scripts will be read one trauma related script (most traumatic experience) and one neutral script (relaxed scene given by participant)

Based on this trial design, predict the completion outcome and termination type (if applicable).